StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a research note released on Friday morning. The brokerage issued a hold rating on the stock. Separately, HC Wainwright reaffirmed a buy rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a research report on Thursday, May 9th. […]

Related Keywords

Fite Biopharma , Exchange Commission , Fite Biopharma Company Profile , Schechter Investment Advisors , Fite Biopharma Ltd , Can Fite Biopharma , Free Report , Get Free Report , Investment Advisors , Can Fite Biopharma Daily ,